Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glaucoma Intensity Treatment Study
2023-510041-16-00Phase 4Authorised
- Sponsor
- Region Västerbotten
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of latanoprost, travoprost, bimatoprost, tafluprost, timolol and 5 more in open-angle glaucoma (OAG), normal tension glaucoma (NTG) and pseudoexfoliation glaucoma (PXG) (2 arms), sponsored by Region Västerbotten. Primary endpoint: Rate of glaucoma progression. Planned start May 2024; status: authorised.
02
Drugs
latanoprosttravoprostbimatoprosttafluprosttimolol
03
Conditions
open-angle glaucoma (OAG)normal tension glaucoma (NTG)pseudoexfoliation glaucoma (PXG)
Beyond the preview
Go deeper on 2023-510041-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510041-16-00.